NCT06625320Phase 3Active not recruiting

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study sponsor: Revolution Medicines, Inc. · RVMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06Estimated
Enrollment · participants500Actual
Source updated2026-06-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Actual enrollment decreased by 1 participants

Before: 501 participants (actual). After: 500 participants (actual).

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 460 participants (planned). After: 501 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview